NCT03517618 is a Phase 2 clinical trial of S-1+leucovorin in Metastatic Colorectal Cancer, sponsored by TTY Biopharm.

Who is sponsoring NCT03517618?

NCT03517618 is sponsored by TTY Biopharm.

What drugs are being tested in NCT03517618?

Interventions in NCT03517618: S-1+leucovorin.

What condition does NCT03517618 study?

NCT03517618 studies Metastatic Colorectal Cancer.

Is NCT03517618 still recruiting?

NCT03517618 is currently completed. Last updated 7 May 2018.

Last reviewed 2018-05-07 · How we verify

NCT03517618

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC

Completed Phase 2 Last updated 7 May 2018

What this trial tests

Phase 2 trial testing S-1+leucovorin in Metastatic Colorectal Cancer in 41 participants. Completed in 18 June 2015.

Timeline

5 July 2014

Primary endpoint
18 June 2015

18 June 2015

Quick facts

Lead sponsor	TTY Biopharm
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	41
Start date	5 July 2014
Primary completion	18 June 2015
Estimated completion	18 June 2015
Sites	1 location across Taiwan

Drugs / interventions tested

S-1+leucovorin — full drug profile →

Conditions studied

Metastatic Colorectal Cancer — all drugs for Metastatic Colorectal Cancer →

Sponsor

TTY Biopharm — full company profile →

Who can join

20 and older, any sex, with Metastatic Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary Objective: To determine disease control rate (DCR) of TS-1® in patients with heavily pre-treated metastatic colorectal cancer Secondary Objectives: * To determine objective response rate (ORR) * To determine time to progression (TTP) * To determine overall survival (OS) * To assess incidence of adverse events (AEs), serious adverse events (SAEs) \[Safety and Tolerability\]

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients.
Hsu HC, Chou WC, Kuan FC, Lee KD, et al · · 2018 · cited 3× · PMID 30538555 · DOI 10.2147/cmar.s179345

Verify or expand the search:

Other recruiting trials for Metastatic Colorectal Cancer

Currently open trials in the same condition.

NCT07416552 — A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) · Phase 1 · recruiting
NCT07314294 — Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients · Phase 2 · recruiting
NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
NCT06959550 — Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorect · Phase 2 · recruiting
NCT06808685 — Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie · recruiting

Other TTY Biopharm trials

Trials by the same sponsor.

NCT06966284 — A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Pat · recruiting
NCT05359627 — A Pharmacokinetic Study of Polymyxin B in Healthy Subjects and Subjects With Renal Insufficiency · Phase 1 · completed
NCT04070313 — A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan · Phase 2 · terminated
NCT03511820 — A Post Marketing Surveillance Study of Lipo-AB® (Amphotericin B) in Neutropenic Patients With Persistent Fever · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03517618 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by TTY Biopharm
Last refreshed: 7 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03517618.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing